Russian State Duma Considers Ban on Sale of E-Cigarettes

Aug.30.2024

Russian State Duma may consider bipartisan bill to ban e-cigarettes nationwide, citing potential health risks including new disease similar to COVID-19.

According to a report by Eadaily on August 30th, the Russian State Duma may consider a bipartisan bill during its autumn session that aims to completely ban the sale of e-cigarettes in Russia.

This information was revealed by Yaroslav Nilov, chairman of the State Duma's Committee on Social Policy and member of the LDPR, one of the drafters of the bill.

Previously, the Russian Ministry of Health warned that e-cigarettes and e-cigarette liquids may trigger a new disease. The department pointed out that e-cigarettes can cause a disease called EVALI, which presents symptoms similar to the novel coronavirus and is due to acute lung injury caused by the use of e-cigarettes.

Nilovf stated that

This initiative is bipartisan, and we are hopeful that it will be discussed this fall.

He added that it is necessary to legislate to ban e-cigarettes as soon as possible before they become fully integrated into people's daily lives.

References:

[1] Госдума РФ рассмотрит законопроект о запрете вейпов

Also Read:

[1] Russia Implements Tax Hike on Tobacco Alternatives starting 2024

[2] China's E-cigarette Export Trade Data Update in July 2024

[3] Russian Interior Ministry proposes controlling 18 psychoactive substances to prevent abuse

[4] Belarus Considers Legislation on E-Cigarettes Amid Health Concerns

[5] Russian Government Considers Tobacco Retail Permit Legislation for Market Protection

[6] Moscow Sets High Fines for Online Tobacco and E-cigarette Sales

[7] Revisions to Federal Law on Smokeless Tobacco Products in Russia

[8] Survey: 64% of Russian smokers want to quit habit

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency

The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.

Dec.02 by 2FIRSTS.ai

NSW Police Seize About US$1.9 Million in Illegal Tobacco Products, Including 15,000 Vapes

During a recent routine traffic stop, New South Wales police discovered a large quantity of illegal tobacco and vapes hidden inside a rental truck, including approximately 942,000 cigarettes and more than 15,000 e-cigarettes, with an estimated value of nearly AUD 2 million. The 31-year-old driver was arrested at the scene and the case has now entered judicial proceedings.

Dec.01 by 2FIRSTS.ai

China Tobacco Accelerates Global Cigar Expansion as CTIHK Becomes Unified Export Platform

After decades of dominance by Cuban and non-Cuban cigars, a new contender is emerging from the East. China Tobacco International (HK) has consolidated the country’s top four cigar brands under one global export platform — a move that could redefine how the world perceives “Chinese cigars.”

Nov.11

Imperial Brands launches ZONE nicotine pouches in the UK, covering the core 9–12 mg strength segment

Imperial Brands has launched its ZONE nicotine pouches in the UK, targeting the mainstream 9–12 mg nicotine strength segment. The brand debuts with five flavours at a recommended retail price of £6.50 per can. Mint variants currently account for around 70% of UK nicotine pouch sales, while fruit flavours are growing rapidly. ZONE will be distributed primarily through independent retail channels.